FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Feb 23, 2026
Summit Therapeutics Inc. (SMMT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$323.6 million. As of Sep 30, 2026 it held $629.8 million in cash and investments and $20.0 million in total debt.
Revenue
$0
Net income
$-1.08B
-387.8% vs prior year
Operating cash flow (TTM)
$-525.17M
-94.7% vs year-ago TTM
Free cash flow (TTM)
$-526.88M
-95.0% vs year-ago TTM
EPS
$-1.44
-364.5% vs prior year
Dividend per share
None
Shares outstanding
775.37M
+5.1% vs prior year
Net cash
$609.80M
as of Sep 30, 2026
Operating margin
-10225.4%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SMMT (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Miami, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1599298
- Former names
- Summit Therapeutics plc (until Sep 17, 2020); Summit Corp plc (until Jan 30, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $705,000 | $1.8M |
| Operating income | — | -$226.0M | -$609.6M | -$72.1M | -$86.2M |
| Net income | -$1.1B | -$221.3M | -$614.9M | -$78.8M | -$88.6M |
| Diluted EPS | -$1.44 | -$0.31 | -$0.99 | -$0.41 | -$0.67 |
| Operating cash flow | -$322.9M | -$142.1M | -$76.8M | -$41.6M | -$72.6M |
| Free cash flow | -$323.6M | -$142.2M | -$76.9M | -$42.2M | -$72.9M |
| Total assets | $751.2M | $435.6M | $202.9M | $664.2M | $113.4M |
| Total liabilities | $92.3M | $46.8M | $125.3M | $537.5M | $30.1M |
| Stockholders' equity | $658.9M | $388.7M | $77.7M | $126.7M | $83.3M |
| Cash and investments | $713.4M | $412.3M | $186.2M | $348.6M | — |
| Total debt | $20.9M | $7.2M | $6.1M | $4.5M | $2.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Bylaw or fiscal year change, Shareholder vote results
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 13, 2026 |
All 564 Summit Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.